分子薬剤学研究室
研究室ページ | English
論文リスト
1.
 Reactive oxygen species are associated with the inhibitory effect of N-(4-hydroxyphenyl)-retinamide on the entry of the severe acute respiratory syndrome-coronavirus 2; Hayashi Y, Huang X, Tanikawa T, Tanigawa K, Yamamoto M, Gohda J, Inoue JI, Fukase K, Kabayama K.; J Biochem., 2023 (in press)
2.
 Nakamura Y, Kihara-Negishi F, Tanigawa K, Kiriya M, Kadowaki Y, Imagawa H, Nakanishi H, Watanabe S, Maruyama K, Karasawa K.; A complex of type I platelet-activating factor acetylhydrolase (PAF-AH) catalytic subunits switches from α1/α2 heterodimer to α2/α2 homodimer during adipocyte differentiation of 3T3-L1 cells. Biol. Pharm. Bull., 46(2): 257-262 (2023)
3.
 Pathogenicity and virulence of Mycobacterium leprae. Mikami M, Tanigawa K, Kawashima A, Kiriya M, Nakamura Y, Fujiwara Y, Suzuki K.; Virulence., 13(1): 1985?2011 (2022)
4.
 Dihydroceramide Δ4-desaturase 1 is not involved in SARS-CoV-2 infection; Hayashi Y, Matsuda K, Tanigawa K, Tanikawa T, Maeda K, Tsuchiya K.; Biol. Pharm. Bull. 45(10):1559-1563 (2022)
5.
 Genome-wide screening identified SEC61A1 as an essential factor for mycolactone- dependent apoptosis in human premonocytic THP-1 cells., Kawashima A, Kiriya M, En J, Tanigawa K, Nakamura Y, Fujiwara Y, Luo Y, Maruyama K, Watanabe S, Goto M, Suzuki K.; PLOS Negl Trop Dis, 16(8):e0010672 (2022)
6.
 Cathepsin G-induced malignant progression of MCF-7 cells involves suppression of PAF signaling through induced expression of PAFAH1B2; Tanigawa K, Kiriya M, Hayashi Y, Shinden Y, Kijima Y, Natsugoe S, Sumimoto T, Morimoto-Kamata R, Yui S, Hama K, Yokoyama K, Nakamura Y, Suzuki K, Nojiri H, Inoue K, Karasawa K., BBA Mol Cell Biol Lipids. 1867(8):159164. (2022)
7.
 Thyroglobulin regulates the expression and localization of the novel iodide transporter SLC26A7 in thyrocytes; Kiriya M, Kawashima A, Fujiwara Y, Tanimura Y, Yoshihara A, Nakamura Y, Tanigawa K, Kondo T, Suzuki K., Endocr J, doi:10.1507/endocrj. EJ22-0082 (2022)
8.
 Thyroid stimulating hormone suppresses the expression and activity of cytosolic sulfotransferase 1a1 in thyrocytes; Nakamura Y, Yoshihara A, Kiriya M, Kawashima A, Tanigawa K, Luo Y, Fujiwara Y, Maruyama K, Watanabe S, Kihara-Negishi F, Karasawa K, Suzuki K., Endocrin J. doi:10.1507/endocrj. EJ22-0055 (2022)
9.
 Regulation of gene expression by follicular thyroglobulin; Kiriya M, Kawashima A, Fujiwara Y, Tanimura Y, Yoshihara A, Nakamura Y, Tanigawa K, Kondo T, Suzuki K., J Endocrinol Thyroid Res. 6(4): 555695 (2022)
10.
 The Role of lipids in the intracellular parasitization of Mycobacterium leprae: Mini-Review; Tanigawa K, Hayashi Y, Kawashima A, Kiriya M, Nakamura Y, Fujiwara Y, Luo Y, Mikami M, Karasawa K, Suzuki K., Appli Microbiol Open Access 8(1), No:1000213 (2022)
11.
 Host-related laboratory parameters for leprosy reactions; Luo Y, Kiriya M, Tanigawa K, Kawashima A, Nakamura Y, Ishii N, Suzuki K., Front Med Article 694376. doi: 10.3389/fmed.2021.694376 (2021)
12.
 Essential roles of PPARs in lipid metabolism during mycobacterial infection; Tanigawa K, Luo Y, Kawashima A, Kiriya M, Nakamura Y, Karasawa K, Suzuki K., Int J Mol Sci, 22(14), 7597 (2021)
13.
 N-(4-Hydroxyphenyl) retinamide suppresses SARS-CoV-2 spike protein-mediated cell-cell fusion by a dihydroceramide Δ4-desaturase 1-independent mechanism; Hayashi Y, Tsuchiya K, Yamamoto M, Nemoto-Sasaki Y, Tanigawa K, Hama K, Ueda Y, Tanikawa T, Gohda J, Maeda K, Inoue J, Yamashita A., J Virol. 9; e0080721 (2021)
14.
 Mycobacterium leprae promotes triacylglycerol de novo synthesis via induction of GPAT3 expression in human premonocytic THP-1 cells; Tanigawa K, Hayashi Y, Hama K, Yamashita A, Yokoyama K, Luo Y, Kawashima A, Maeda Y, Nakamura Y, Harada A, Kiriya M, Karasawa K, Suzuki K., PLoS One. 16(3): e0249184 (2021)
15.
 Deficiency of type I platelet-activating factor-acetylhydrolase catalytic subunits causes an increase in body weight; Nakamura Y, Momoko Y, Tanigawa K, Harada H, Kihara-Negishi F, Maruyama K, Karasawa K., Biol. Pharm. Bull. 44(7):920-925 (2021)
16.
 The function of peroxisome proliferator-activated receptor (PPAR)-gamma and PPAR-delta in Mycobacterium leprae-induced foam cell formation in host macrophages; Luo Y, Tanigawa K, Ishido Y, Ishikawa K, Kawashima A, Ishii N, Suzuki K., PLoS Negl Trop Dis. 14(10):e00088502020 (2020)
17.
 Transcriptional Regulation of Acyl-CoA:Glycerol-sn-3-Phosphate Acyltransferases; Karasawa K, Tanigawa K, Harada A, Yamashita A., Int J Mol Sci. 20(4). 964 (2019)
18.
 Naturally occurring a loss of a giant plasmid from Mycobacterium ulcerans subsp. shinshuense makes it non-pathogenic; Nakanaga K, Ogura Y, Toyoda A, Yoshida M, Fukano H, Fujiwara N, Miyamoto Y, Nakata N, Kazumi Y, Maeda S, Ooka T, Goto M, Tanigawa K, Mitarai S, Suzuki K, Ishii N, Ato M, Hayashi T, Hoshino Y., Sci Rep. 8(1):8218 (2018)
19.
 Expression of a novel 90-kDa protein, Lsd90, involved in the metabolism of very long-chain fatty acid-containing phospholipids in a mitosis-defective fission yeast mutant; Yokoyama, K., Nakagawa, M., Satoh, M., Saitoh, S., Dohmae, N., Harada, A., Satoh, N., Karasawa, K., Takio, K., Yanagida, M., Inoue, K.: J. Biochem. 143(3) 369-375 (2008)
20.
 Clinical aspects of plasma platelet-activating factor-acetylhydrolase; Karasawa, K.: Biochim. Biophys. Acta. 1761(11) 1359-1372 (2006)
21.
 Adenovirus-mediated gene transfer and lipoprotein-mediated protein delivery of plasma PAF-AH ameliorates proteinuria in rat model of glomerulosclerosis; Iso-O, N., Noto, H., Hara, M., Togo, M., Karasawa, K., Ohashi, N., Noiri, E., Hashimoto, Y., Kadowaki, T., Kimura, S., Watanabe, T. and Tsukamoto, K.: Mol. Ther. 13(1) 118-126 (2006)
22.
 Red blood cells highly express type I platelet-activating factor-acetylhydrolase (PAF-AH) which consists of the alpha1/alpha2 complex; Karasawa, K., Shirakura, M., Harada, A., Satoh, N., Yokoyama, K., Setaka, M. and Inoue, K.: J Biochem (Tokyo). 138(4) 509-517 (2005)
23.
 Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits; ･ Arakawa, H., Qian, J.Y., Baatar, D., Karasawa, K., Asada, Y., Sasaguri, Y., Miller, E.R., Witztum, J.L. and Ueno, H.: Circulation 111(24) 3302-3309 (2005)
24.
 Plasma platelet activating factor-acetylhydrolase (PAF-AH); Karasawa, K., Harada, A.,
Satoh, N., Inoue, K. and Setaka, M.: Prog. Lipid Res. 42(2) 93-114 (2003)
25.
 Regulation of activities of cytidine 5'-diphospho-choline:1-O-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase, an enzyme responsible for de novo synthesis of platele-activating factor, by membrane phospholipids; Satoh, N., Harada, A., Yokoyama, K., Karasawa, K., Inoue, K. and Setaka, M.: J. Health Sci. 49(1)
26.
 Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress; Noto, H., Hara, M., Karasawa, K., Iso-O, N., Satoh, H., Togo, M., Hashimoto, Y., Yamada, Y., Kosaka, T., Kawamura, M., Kimura, S. and Tsukamoto, K.: Arterioscler. Thromb. Vasc. Biol. 23(5) 829-35 (2003)
27.
 Transfection of the plasma-type platelet-activating factor acetylhydrolase gene attenuates glutamate-induced apoptosis in cultured rat cortical neurons; Hirashima, Y., Ueno, H., Karasawa, K., Yokoyama, K., Setaka, M. and Takaku, A.: Brain Res. 885(1) 128-132 (2000)
28.
 Platelet-activating factor (PAF)-dependent transacetylase and its relationship with PAF acetylhydrolases; Bae, K., Longobardi, L., Karasawa, K., Malone, B., Inoue, T., Aoki, J., Arai, H., Inoue, K. and Lee, T.: J. Biol. Chem. 275(35) 26704-26709 (2000)
29.
 Nadrin, a novel neuron-specific GTPase-activating protein involved in regulated exocytosis; Harada, A., Furuta, B., Takeuchi, K., Itakura, M., Takahashi, M. and Umeda, M.: J. Biol. Chem. 275(47) 36885-36891 (2000)
30.
 The Escherichia coli pldC gene encoding lysophospholipase L1 is identical to the apeA and tesA genes encoding protease I and thioesterase I, respectively; Karasawa, K., Yokyama, K., Setaka, M. and Nojima, S.: J. Biochem. 126(2) 445-448 (1999)
31.
 Purification and characterization from rat kidney membranes of a novel platelet-activating factor (PAF)-dependent transacetylase that catalyzes the hydrolysis of PAF, formation of PAF analogs, and C2-ceramide; Karasawa, K., Qiu, X and Lee, T. J. Biol. Chem. 274(13) 8655-8661 (1999).
32.
 Metabolism of Oxidized Phosphatidylcholines Formed in Oxidized Low Density Lipoprotein by Lecithine-Cholesterol Acyltransferase; Itabe, H., Hosoya, R., Karasawa, K., Jimi, S., Uesugi, N., Takabayashi, S., Imanaka, T., and Takano, T. J.Biochem. 126 153-161 (1999)
33.
 Deficient Platelet-Activating Factor and Related Enzymes in Hemimegalencephacy; Hirashima, Y., Endo, S., Karasawa, K., Sato, N., Yokoyama, K., Kurimoto, M., Ikeda, H., Setaka, M., and Takaku, A.: Child’s Nerv.Syst. 15 98-102 (1999)
34.
 Changes in Composition of Newly Synthesized Sphingolipids of HeLa Cells during the Cell Cycle: Suppression of Sphingomyeline and Higher-Glycosphingolipid Synthesis and Accumulation of Ceramide and Glucosylceramide in Mitotic Cells; Yokoyama, K., Suzuki, M., Kawashima, I., Karasawa, K., Nojima, S., Enomoto, T., Tai, T., Suzuki, A., and Setaka, M., Eur.J.Biochem. 249 450-455 (1997)
35.
 Activated Mast Cells Release Extracellular Type Platelet-Activating Factor Acetylhydrolase That Contributes to Autocline Inactivation of Platelet-Activating Factor; Nakajima, K., Murakami, M., Yanoshita, R., Samejima, Y., Karasawa, K., Setaka, M., Nojima, S., and Kudo, I.: J.Biol.Chem. 272 19708-19713 (1997)
36.
 Cloning, Expression and Characterization of Plasma Platelet-Activating Factor Acetylhydrolase from Guinea Pig; Karasawa, K., Kuge, O., Kawasaki, K., Nishijima, M.,
Nakano, Y., Tomita, M., Yokoyama, K., Setaka, M., and Nojima, S.: J.Biochem. 120 838-844 (1996)
37.
 A Distribution Study of 11C Platelet-Activating Factor (PAF) Analogs in Normal and Tumor-Bearing Mice; Sasaki, T., Tohyama, T., Oda, K., Toyama, H., Ishii, S., Senda, M., Karasawa, K., Satoh, N., Setaka, M., Nojima, S., Nozaki, T., and Braquet, P.: Nucl.Med.Biol. 23, 309-314 (1996)
38.
 Platelet-Activating Factor (PAF) and the Development of Chronic Subdural Haematoma.; Hirashima, Y., Endo, S., Kato, R., Ohmori, T., Nagahori, T., Nishijima, M., Karasawa, K.,
Nojima, S., and Takaku, A.: Acta Neurochir.129 20-25 (1994)
39.
 Purification and Characterization of Platelet-Activating Factor (PAF) Acetylhydrolase from Peritoneal Fuid Obtained from Guinea pig after Endotoxin Shock.; Karasawa, K., Yato, M., Setaka, M., and Nojima, S.: J.Biochem. 116 374-379 (1994)
40.
 Accumulation of Platelet-activating Factor (PAF) Acetylhydrolase in the Peritoneal Cavity of Guinea Pig after Endotoxin Shock.; Karasawa, K., Kato, H., Setaka, M., and Nojima, S.: J.Biochem. 116 368-373 (1994)
41.
 Antibodies to PAF and PAF-Associated Diseases.; Nojima, S., Karasawa, K., Satoh, N.,
Setaka, M., Hirashima, T., and Takaku, A.: J.Lipid Mediators Cell Signalling 10 191-192 (1994)
42.
 PAF-Acetylhydrolase Activities Accumulate in the Peritoneal Cavity after E.coli LPS Administration.; Karasawa, K., Satoh, N., Setaka, M., and Nojima, S.: J.Lipid Mediators Cell Signalling 10 107-108 (1994)
43.
 The Role of Platelet-Activating Factor (PAF) in the Development of Chronic Subdural Hematoma.; Hirashima, Y., Kato, R., Ohmori, T., Nagahori, T., Nishijima, M., Endo, S., Takaku, A., and Karasawa, K.: in Recent Advances in Neurotraumatology 61-64 (1993)
44.
 Immunofluorescent Localization of Platelet-Activating Factor (PAF) in the Rat.; Hirashima, Y., Kato, R., Endo,S., Takaku, A., Karasawa, K., and Nojima, S.: Histochem.J. 25, 830-833 (1993)
45.
 Platelet-Activating Factor and Cerebral Vasopasm following Subarachnoid Hemorrhage.; Hirashima, Y., Endo, S., Otsuji, T., Karasawa, K., Nojima, S., and Takaku, A.: J.Neurosurg., 78, 592-597 (1993)
46.
 Synthesis of [11C]Platelet-Activating Factor (PAF) Analogues for in vivo Imaging of PAF Receptors.; Sasaki, T., Karasawa, K., Ishiwata, K., Satoh, N.,Ishii, S., Ogawa, K., Nozaki, T., Setaka, M., Nojima, S., and Senda, M.: J.Labelled Compounds and Radiopharmaceuticals 33 921-931 (1993)
47.
 Possible Influence of Lysophospholipase on the Production of 1-Acyl-2- Acetylglycerophosphocholine in Macrophages.; Nakagawa, Y., Sugai, M., Karasawa, K., Tokumura, A., Tsukatani, H., Setaka, M., and Nojima, S.: Biochim.Biophys.Acta 1126 277-285 (1992)
48.
 Radioimmunoassay for Platelet-Activating Factor (PAF).; Karasawa, K., Satoh, N., Hongo, T., Nakagawa, Y., Setaka, M., and Nojima, S.: Lipids 26 1126-1129 (1991)
49.
 Specific Binding of Antibodies to Platelet-Activating Factor (PAF) as Demonstrated by
Thin-layer Chromatography/Immunostaining.; Karasawa, K., Satoh, N., Hongo, T., Nakagawa, Y., Setaka, Y., and Nojima, S.: Lipids 26 1122-1125 (1991)
50.
 Antibodies to Synthetic Platelet-Activating Factor (1-O-Alkyl-2-O-Acetyl-sn-Glycero-3-Phosphocholine) Analogues with Substituents at the sn-2 Position.; Karasawa, K., Satoh, N., Masuda, M., Hashimoto, K., Ishibashi,K., and Nojima, S.: J.Biochem. 110 683-687 (1991)
51.
 Lysophospholipases from Escherichia coli.; Karasawa, K., and Nojima, S.: Methods Enzymol. 197 437-445 (1991)
52.
 Lysophospholipase L1 from Escherichia coli K-12 Overproducer.; Karasawa, K., Kudo, I., Kobayashi, T., Homma, H., Chiba, N., Mizushima, H., Inoue, I., and Nojima, S.: J.Biochem. 109 288-293 (1991)
53.
 Antibodies to Platelet-Activating Factor.; Karasawa, K., Satoh, N., Hongo, T., Setaka, M., Mowri, H., Takano, T., Hashimoto, S., Ikegami, S., Fujita, K., and Ohno, M.: in Trends in Pharmacological Research on Platelet-Activating Factor in Japan.138-146 (1988)
54.
 Antibody to Platelet-Activating Factor (1-O-Alkyl-2-O-Acetyl-sn-Glycero-3- Phosphocholine; PAF).; Karasawa, K., Fujita, K., Satoh, N., Hongo, T., Setaka, M., Ohno, M., and Nojima, S.: J.Biochem. 102 451-453 (1987)
著書リスト・その他
1.
 酵素と酵素反応、遺伝情報の発現と調節、唐澤　健、生化学演習、野尻久雄　編集、pp.105-149、278-316、京都廣川書店、2013
2.
 固形製剤、唐澤　健、製剤学・物理薬剤学　[第２版]、栄田敏之、唐澤健、岡本浩一　編集、
pp. 127-172、廣川書店、（2012）
3.
 粒子の性質、唐沢　健、物理薬剤学・製剤学?計算問題の解法、唐澤健、坂根稔康　編集、
pp. 61-78、廣川書店、（2012）
4.
 物質の溶解、唐沢　健、製剤化のサイエンス　改訂3版、寺田　勝英、高山　幸三　編、pp.14-53、
ネオメディカル、(2007)
5.
 溶液と溶解現象、唐沢　健、NEW パワーブック　物理薬剤学・製剤学、金尾　義治、北河　修治　編、pp.113-153、廣川書店、(2007)
6.
 反応速度、瀬高　守夫、唐沢　健、現代薬学シリーズ9　物理化学［第2版］、宮崎　利夫　総編集、pp.110-130、朝倉書店、(2002)
7.
 抗酸化酵素パラオキソナーゼの基質はなにか？唐沢　健、ファルマシア、252-253、(2002)
8.
 血小板活性化因子(PAF)の新たな代謝経路とその生理的意義-PAF依存性トランスアセチル化反応、唐沢　健、蛋白質・核酸・酵素、46巻、55-60、(2000）
9.
 炎症誘発因子としての血小板活性化因子、唐沢　健、油化学、49巻、13-22 (2000)
10.
 喘息重症化因子としての血漿PAFアセチルハイドロラーゼ、唐沢　健、ファルマシア、
1263-1264、(1999)
11.
 リゾホスホリパーゼ、唐沢　健、生物薬化学講座「脂質I」第3章、220-227、(1998)
12.
 血清脂質-PAF（血小板活性化因子）、唐沢　健、野島庄七、The Lipids、4巻、372-378、(1993)
13.
 血管内皮細胞-血小板活性化因子（PAF）、唐沢　健、野島　庄七、臨床検査、36巻、
384-390、(1992)
14.
 アルキルアセチルグリセロホスホコリン免疫化学的方法による定量法、唐沢　健、野島　庄七、
新生化学実験講座4　脂質IIリン脂質、日本生化学会　編、pp.189-197、東京化学同人、(1991)
15.
 抗PAF抗体の調製とその応用、唐沢　健、野島　庄七、蛋白質・核酸・酵素、36巻、
516- 523、(1991)
16.
 PAFの測定法、唐沢　健、野島　庄七、最新医学、45巻、449-455 (1990)
17.
 血小板活性化因子 (PAF) の生理活性と抗体の調製について、唐沢　健、リン脂質研究の進歩、7巻、7-30、（(1989)
18.
 PAFの病態への関与とPAF拮抗薬、唐沢　健、野島　庄七、BIOmedica、3巻、1262-1268、(1988)
19.
 PAFの化学・分析法-抗体、唐沢　健、佐藤　典子、本郷　敏雄、瀬高　守夫、野島　庄七、
現代化学増刊17巻、35-38、(1988)
20.
 リゾホスホリパーゼ、唐沢　健、蛋白質・核酸・酵素、32巻、1091-1096 (1987)
21.
 PAFの生化学と病態生理作用、唐沢　健、野島　庄七、感染・炎症・免疫、17巻、119-128、(1987)
22.
 リゾホスホリパーゼ、唐沢　健、小林　哲幸、続生化学実験講座3　膜脂質と血漿リポタンパク質(上)、日本生化学会　編、pp.239-243、東京化学同人、(1986)